Evidence map›Paper›PMID 39728764›Full record

ArticleToxins2024

Stable Convergent Polyneuronal Innervation and Altered Synapse Elimination in

Brigitte Girard, Aurélie Couesnon, Emmanuelle Girard, Jordi Molgó

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brigitte GirardService d'Ophtalmologie, Hôpital Tenon, Sorbonne Université, Université Pierre et Marie Curie, 4 rue de la Chine, 75020 Paris, France.ORCID 0000-0002-2324-3158
Aurélie CouesnonInstitut des Neurosciences Paris-Saclay, UMR 9197, CNRS/Université Paris-Sud, 91198 Gif-sur-Yvette, Cedex, France.
Emmanuelle GirardInstitut NeuroMyoGene-Physiopathology & Genetic of Neuron and Muscle, CNRS UMR5261, INSERM U1315, Université Lyon1, 8 Avenue Rockefeller, 69008 Lyon, France.ORCID 0000-0001-6730-9596
Jordi MolgóInstitut des Neurosciences Paris-Saclay, UMR 9197, CNRS/Université Paris-Sud, 91198 Gif-sur-Yvette, Cedex, France.ORCID 0000-0002-0693-8994

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulinum neurotoxin type-A (BoNT/A), which blocks quantal acetylcholine (ACh) release at the neuromuscular junction (NMJ), has demonstrated its efficacy in the symptomatic treatment of blepharospasm. In 3.89% of patients treated for blepharospasm at Tenon Hospital, BoNT/A was no longer effective in relieving the patient's symptoms, and a partial upper myectomy of the

Indexed as

BlepharospasmBotulinum Toxins, Type ANeuromuscular JunctionAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeuromuscular AgentsOculomotor MusclesSynapsesabobotulinumtoxinABotulinum Toxins, Type AincobotulinumtoxinANeuromuscular Agentsblepharospasmbotulinum type-A neurotoxinconvergent innervationhuman Orbicularis oculi musclemyectomynerve sproutingneuromuscular junctionnicotinic acetylcholine receptorspolyneuronal innervationskeletal musclesynapse elimination

Identifiers

PMID39728764
PMCPMC11728458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.